Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year

Najeeda Yasmeen, Laura M. Sawyer*, Kinga Malottki, Lars Åke Levin, Eydna Didriksen Apol, Gregor B. Jemec

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

40 Citationer (Scopus)
17 Downloads (Pure)

Abstract

Purpose: To compare PASI outcomes of approved biologics and apremilast after 1 year of treatment. Methods: A systematic review identified RCTs and long-term extensions reporting PASI 75, 90, and 100 responses in adults with moderate-to-severe psoriasis. Data for analysis were modeled using a Bayesian multinomial likelihood model with probit link. Results: Twenty-eight studies reporting PASI responses were included in the network meta-analysis. Differences in study design led to a stepwise approach to synthesis, consisting of two analyses. The primary analysis included nine RCTs investigating comparative efficacy at 1 year. Results indicated risankizumab, brodalumab, and guselkumab were the most effective therapies, followed by ixekizumab and secukinumab; all demonstrated superiority to ustekinumab and etanercept. The secondary analysis extended the primary analysis with 19 further studies comparing active interventions to placebo outcomes extrapolated from induction. The interventions generating the highest PASI response were the same as the primary analysis. These therapies were more effective than apremilast, ustekinumab, adalimumab, certolizumab, etanercept, and infliximab. Conclusions: This NMA demonstrated that evaluated IL-17 and IL-23 inhibitors outperformed other biological therapies after 1 year. Risankizumab had a higher probability of achieving PASI outcomes than all other biologics, except brodalumab and guselkumab, where no significant difference could be concluded.

OriginalsprogEngelsk
TidsskriftJournal of Dermatological Treatment
Vol/bind33
Udgave nummer1
Sider (fra-til)204-218
Antal sider15
ISSN0954-6634
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
This study was funded by LEO Pharma A/S. The authors thank Jana Tillotson for graphic design support during the preparation of this article.

Publisher Copyright:
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Citationsformater